Tradeshift Joins FRDM to Launch App to Help Address Slavery in Supply Chains
As human trafficking continues to plague communities worldwide, Tradeshift, the leader in supply chain payments and marketplaces, has partnered with FRDM (formerly Made In A Free World) to announce today plans to help businesses detect and mitigate human trafficking in their global supply chains. The FRDM-developed app, built on the Tradeshift platform, enriches the entire Tradeshift ecosystem by allowing any business on the Tradeshift platform to simply turn on the app to start monitoring human trafficking. For many businesses, FRDM makes it far easier for internal stakeholders--like Chief Sustainability Officers--to persuade CIOs, CPOs, and CMOs to start treating supply chain slavery as an essential corporate medicine to take for the health of their entire supply chain.
The FRDM-developed app allows companies to proactively create an early detection of supply chain risk in human trafficking. It brings the most comprehensive forced labor database analytics capability to Tradeshift’s innovative supply chain network, without requiring customers to manually integrate their procurement solution with the database. As an app, it is easy to activate and use on day one, requiring no integration.
The app is specifically designed to analyze purchase data, atomize risks, and protect corporate values while ensuring compliance with international regulations. With FRDM, Tradeshift users can trace and monitor social risks at every level of their supply chain, from raw materials to finished goods. The application combines global trade flow data with supplier and purchase level details to provide enterprises with multi-tiered visibility.
“We provide a platform for a community of businesses and consumers to buy better through the use of FRDM,” said Justin Dillon, CEO of FRDM. “This idea started in 2011 when the organization I founded partnered with the U.S. State Department to build the Slavery Footprint platform, combining product data with consumer purchase data to provide footprints of close to 30 million people worldwide. In joining with Tradeshift, we aim to make these tools available to the world’s most influential corporations. Consumers, investors, and governments expect companies to act on this.”
With an estimated 16 million slave laborers layered into global supply chains, legislation from the US to the UK to Australia requires businesses to provide transparency into their operations by reporting on the actions they are taking to address modern slavery in their business and supply chain.
“No company ever says that slavery-based revenue is OK,” said Tradeshift CEO, Christian Lanng. “But companies still don’t take action because it’s just too complicated to marry the analytics with the purchasing decisions. We believe that making this step frictionless is not just a compliance question from a business operations perspective, but, more importantly, a fundamental moral issue. And it’s one that must be resolved. We can help do that and this partnership is confirmation of our commitment.”
Tradeshift drives supply chain innovation for the digitally connected economy. As the leader in supply chain payments and marketplaces, the company helps buyers and suppliers digitize all their trade transactions, collaborate on every process, and connect with any supply chain app. More than 1.5 million companies across 190 countries trust Tradeshift to process over half a trillion USD in transaction value, making it the largest global business network for buying and selling. Discover commerce for all at tradeshift.com.
FRDM is a supply chain risk analysis and monitoring platform designed to monitor Environmental, Social, and Governance risks within supply chains. FRDM is the only platform offering end-to-end risk optics including: primary inputs, products, product categories, and suppliers. Customers can explore their company’s risk through intuitive data visualizations and push alerts via the FRDM dashboard. FRDM assists with reputation management, regulatory compliance, and risk mitigation against challenges like forced and child labor in supply chains. FRDM helps companies buy better by building a values-aligned supplier network. frdm.co
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimini Street CEO Visits Seoul, Addresses Changing IT Mission19.3.2019 23:00:00 CET | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, is committed to helping South Korean companies reduce ongoing IT operating costs and freeing up significant IT budget to invest in innovation, competitive advantage and growth, co-founder and CEO Seth A. Ravin explained during a press conference in Seoul. Mr. Ravin also highlighted continued strong and growing demand in Korea for the Company’s award-winning, ultra-responsive enterprise software support model, which is disrupting the $160 billion enterprise software maintenance market worldwide. As the 4th largest economy in Asia, and the 11th largest in the world, South Korea represents a large market opportunity for the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005832/en/ Rimini Street CEO Visits Seoul,
SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer19.3.2019 20:00:00 CET | Pressemelding
SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50 th Annual Meeting on Women's Cancer today. Final analysis of SOV02 shows that DCVAC/OvCa decreased the risk of death significantly compared to patients who did not receive DCVAC/OvCa. Clinical trial results were presented during today’s SGO 2019 Plenary Session by SOV02 principal investigator David Cibula, MD, PhD from General University Hospital in Prague (Czech Republic). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005837/en/ In the randomized, open label SOV02 clinical trial, patients with recurrent ovarian cancer received DCVAC/OvCa in combination with platinum-based chemotherapy. Compared to patients who did not receive DCVAC, it decreased the risk of death by 62%. The combinati
OCP Announces Date of Fourth Quarter and Full Year 2018 Earnings19.3.2019 19:00:00 CET | Pressemelding
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2018 results on Monday, March 25, 2019. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 2:00 p.m. Morocco time (GMT+1), and 1:00 p.m. London time (GMT). OCP senior management will host a conference call to discuss fourth quarter and full year 2018 results at 10:00 a.m. EDT, 3:00 p.m. Morocco time (GMT+1), and 2:00 p.m. London time (GMT) on Monday, March 25, 2019 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing firstname.lastname@example.org About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s
HCL and Xerox Expand Strategic Partnership to Accelerate Operational Transformation19.3.2019 16:51:00 CET | Pressemelding
HCL Technologies (HCL), a leading global technology company, announced that it signed a managed services agreement with Xerox (NYSE: XRX). Under the terms of the agreement, HCL will manage portions of Xerox’s shared services, including global administrative and support functions, including, among others, selected information technology and finance functions (excluding accounting). Leveraging HCL’s global scale and capabilities, Xerox will strategically evolve its shared services into process-first, technology-led digital operations. This seven-year agreement for an incremental $1.3 billion continues to build on the success of the Xerox-HCL relationship, which began in 2009 with product engineering and support services. Under that agreement, HCL currently manages aspects of Xerox’s mechanical, electrical and software engineering activities for printer and imaging product lines. Together, HCL and Xerox have delivered 215 U.S. patents and have created world-class R&D labs that are tightly
Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases19.3.2019 15:18:00 CET | Pressemelding
Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory diseases, including juvenile idiopathic arthritis. The 18-month program includes: development of a research cell bank using Abzena’s proprietary cell line and ambr® 15 automated high throughput bioreactors, generation of master cell banks, scale up using an ambr® 250 during process development, followed by cGMP manufacturing in Sartorius 500 L single use stirred tank bioreactors for clinical material. The work will take place at Abzena’s sites in Cambridge, UK and San Diego, USA. Jonathan Goldman, CEO of Abzena, said: “Autoimmune inflammatory diseases such as juvenile idiopathic arthritis represent significant unmet medical need. We are